Oncolytic measles virus strains have significant antitumor activity against glioma stem cells

Gene Therapy

Volumn 20, Issue 4, 2013, Pages 444-449

  Allen, C ^a   Opyrchal, M ^a   Aderca, I ^a   Schroeder, M A ^a   Sarkaria, J N ^a   Domingo, E ^a   Federspiel, M J ^a   Galanis, E ^a  

^a MAYO CLINIC   (United States)

Author keywords

gliomas; measles virus; MV CEA; MV NIS; stem cells

Indexed keywords

CD133 ANTIGEN; NESTIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC PARAMYXOVIRUS; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CAUDATE NUCLEUS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; GIANT CELLS; GLIOBLASTOMA; HUMANS; MEASLES VIRUS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MEASLES VIRUS; MUS; MUS MUSCULUS;

EID: 84875947090     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.62     Document Type: Article

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: a Cancer Journal for Clinicians 2011; 61: 212-236.
2. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer cell 2009; 15: 45-56.
3. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-7848.
4. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-375.
5. Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opinion Biol Ther 2008; 8: 213-220.
6. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW et al. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Mol Ther 2007; 15: 677-686.
7. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoem-bryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-2469.
8. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
9. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009; 69: 82-91.
10. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nature Med 2002; 8: 527-531.
11. Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protocols Pharm/editorial board, S.J. Enna 2011; Chapter 14: Unit 14 16.
12. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005; 7: 164-176.
13. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
14. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-4015.
15. Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006; 10: 454-456.
16. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY et al. Molecular properties of CD133 + glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neuro-oncol 2009; 94: 1-19.
17. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF et al. Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26: 3015-3024.
18. Sakariassen PO, Immervoll H, Chekenya M. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia 2007; 9: 882-892.
19. Ying M, Wang S, Sang Y, Sun P, Lal B, Goodwin CR et al. Regulation of glio-blastoma stem cells by retinoic acid: role for Notch pathway inhibition. Oncogene 2011; 30: 3454-3467.
20. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011; 17: 3686-3696.
21. Wakimoto H, Kesari S, Farrell CJ, Curry Jr. WT, Zaupa C, Aghi M et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 2009; 69: 3472-3481.
22. Dhiman N, Jacobson RM, Poland GA. Measles virus receptors: SLAM and CD46. Rev Med Virol 2004; 14: 217-229.
23. Yanagi Y, Takeda M, Ohno S. Measles virus: cellular receptors, tropism and pathogenesis. J Gen Virol 2006; 87: 2767-2779.
24. Schneider U, von Messling V, Devaux P, Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J Virol 2002; 76: 7460-7467.
25. Yanagi Y. The cellular receptor for measles virus. Uirusu 2001; 51: 201-208.
26. Ulasov IV, Tyler MA, Zheng S, Han Y, Lesniak MS. CD46represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther 2006; 17: 556-564.
27. Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 1991; 147: 3005-3011.
28. Fishelson Z. Complement C3: a molecular mosaic of binding sites. Mol Immunol 1991; 28: 545-552.
29. Oglesby TJ, White D, Tedja I, Liszewski K, Wright L, Van den Bogarde J et al. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor. Trans Assoc Am Phys 1991; 104: 164-172.
30. Galanis E, O'Neill BP, Piepgras D, Meyer FB, Uhm JH, Marks R et al. Phase I intratumoral and resection cavity administration of a measles virus derivative expressing the human carcionembroyonic antigen (CEA) in patients with recurrent glioblastoma multiforme. (Abstract MA-15). Neuro-Oncology 2008; 10: 819.
31. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011; 480: 530-533.
32. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010; 134: 835-845.
33. Fabre-Lafay S, Garrido-Urbani S, Reymond N, Goncalves A, Dubreuil P, Lopez M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 2005; 280: 19543-19550.
34. Takano A, Ishikawa N, Nishino R, Masuda K, Yasui W, Inai K et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009; 69: 6694-6703.
35. Togashi H, Sakisaka T, Takai Y. Cell adhesion molecules in the central nervous system. Cell Adh Migr 2009; 3: 29-35.
36. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncology 2005; 7: 164-176.
37. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009; 17: 2041-2048.